A Class III PMA Is Not a Business Strategy May 25, 2026

Srilekha Deka, MD, PhD

Script Molecular is a biotech consulting firm in San Francisco, CA.

Pathway

Too many early-stage medtech companies confuse the hardest regulatory pathway with the smartest one. That mistake can burn capital, delay revenue, and hand market momentum to competitors who choose a more strategic route.

Under FDA’s framework, PMA is the most stringent premarket pathway and is used for Class III devices. FDA states that PMA is the scientific and regulatory review process used to evaluate the safety and effectiveness of Class III devices, which are those that support or sustain human life, are of substantial importance in preventing impairment of human health or present a potential unreasonable risk of illness or injury.

By contrast, many devices may be better suited to a 510(k) or De Novo pathway depending on their risk profile, intended use, and whether a legally marketed predicate exists. FDA explains that a 510(k) is used to demonstrate substantial equivalence to a legally marketed device, while De Novo provides a pathway for novel devices when no suitable predicate exists.

The wrong question

The wrong question is, “Which pathway sounds most innovative?”

The better question is, “Which pathway gets us to patients, evidence, reimbursement, and growth with the least avoidable friction?” FDA’s own medical device overview emphasizes that developers must identify the device classification and regulatory pathway early, then generate valid scientific evidence to support the submission.

That means regulatory strategy cannot sit apart from commercialization strategy. A device that takes longer to clear may not just delay launch; it may delay reimbursement discussions, adoption, revenue, and the clinical evidence needed for the next stage of growth.

Why PMA is different

PMA is not just “harder.” It is materially more demanding. FDA describes PMA as the most stringent type of device marketing application, and PMA submissions must include scientific documentation showing safety and effectiveness; for many devices, that means substantial clinical evidence.

That level of burden is appropriate for certain high-risk devices. But for many early-stage companies, pursuing PMA before fully testing whether a 510(k) or De Novo path is viable can create avoidable delays and funding pressure. FDA’s framework makes clear that pathway selection should be driven by classification and evidence needs, not ambition alone.

The business consequences

I have seen companies spend years pursuing a PMA while competitors entered the market earlier through a more strategic pathway. Those competitors generated revenue sooner, built physician adoption, collected real-world evidence, and strengthened their position before expanding indications.

That sequencing matters. Early commercial traction can reduce risk, improve negotiating leverage with investors, and generate evidence that supports future expansion. In many cases, the smartest long-term strategy is to enter earlier with the right pathway, then build toward broader claims later.

A better framework

A smarter regulatory strategy aligns five things:

  1. Risk classification
  2. Evidence generation
  3. Reimbursement strategy
  4. Commercialization timing
  5. Capital efficiency

When those five are aligned, regulatory work becomes a growth lever instead of a cost center. When they are misaligned, the company may spend heavily to reach a pathway that looks impressive on paper but weakens the business.

Bottom line

Class III does not automatically mean more innovative. It usually means more regulatory burden. The strongest companies are not the ones that choose the toughest pathway for its own sake. They are the ones that choose the pathway they can execute, fund, and scale.

How did your team decide between PMA, De Novo, and 510(k)?

References